Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Investigating biomarkers of Phase II endocrine resistance in breast cancer

A postgraduate research opportunity at the University of Otago.

Details

Close date
Thursday, 30 April 2020
Academic background
Sciences, Health Sciences
Host campus
Dunedin
Qualification
Master’s
Department
Pathology (Dunedin)
Supervisor
Dr Heather Cunliffe

Overview

Phase II endocrine resistance is a phenomenon observed in a proportion of breast cancer patients following long term estrogen deprivation therapy, whereupon re-exposure to a short-term pulse of physiological estrogen causes their tumours to apoptose. Moreover, this treatment results in resensitisation of tumour cells to anti-estrogen threapy.

This project will leverage laboratory models of Phase II resistant breast cancer to investigate genes and cellular pathways altered in phase II vs. Phase I (estrogen-stimulated) disease. Findings will contribute to an ongoing international collaborative study to define translational biomarkers to identify patients whose disease has evolved from phase I to Phase II resistance.

Contact

Heather Cunliffe
Email   heather.cunliffe@otago.ac.nz